Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis
- PMID: 8239626
- PMCID: PMC188115
- DOI: 10.1128/AAC.37.9.2024
Use of single-dose ofloxacin to eradicate tonsillopharyngeal carriage of Neisseria meningitidis
Abstract
After an outbreak of three cases of serogroup B meningococcal disease at a Norwegian college, 84 of 392 (21%) subjects were tonsillopharyngeal carriers of Neisseria meningitidis. To eradicate meningococcal carriage, 80 volunteers received a single dose of 400 mg of ofloxacin. Three days after treatment, all 75 evaluable volunteers were culture negative for N. meningitidis, and after 7 days none carried the strain that they carried initially, as judged by DNA fingerprinting. A single dose of ofloxacin was found to be 97.2% effective in eradicating carriage of N. meningitidis for a period of 33 days. The carriage acquisition rate among treated students was four times higher than that among nontreated noncarriers (P = 0.02). After ofloxacin treatment, no case of meningococcal disease occurred for 6 months. Ofloxacin may thus prevent the outbreak and spread of meningococcal disease.
Similar articles
-
Single dose ofloxacin in the eradication of pharyngeal carriage of Neisseria meningitidis.Drugs. 1995;49 Suppl 2:399-400. doi: 10.2165/00003495-199500492-00112. Drugs. 1995. PMID: 8549376 Clinical Trial. No abstract available.
-
Single dose ciprofloxacin for the eradication of pharyngeal carriage of Neisseria meningitidis.J Antimicrob Chemother. 1988 Apr;21(4):489-96. doi: 10.1093/jac/21.4.489. J Antimicrob Chemother. 1988. PMID: 3132442
-
Meningococcal carriage in Umra pilgrims returning from Saudi Arabia.J Travel Med. 2003 May-Jun;10(3):147-9. doi: 10.2310/7060.2003.35751. J Travel Med. 2003. PMID: 12757687
-
Neisseria meningitidis infection: who, when and where?Expert Rev Anti Infect Ther. 2015;13(10):1249-63. doi: 10.1586/14787210.2015.1070096. Epub 2015 Jul 18. Expert Rev Anti Infect Ther. 2015. PMID: 26190347 Review.
-
An unwanted guest: Neisseria meningitidis - carriage, risk for invasive disease and the impact of vaccination with insight on Italy incidence.Expert Rev Anti Infect Ther. 2017 Jul;15(7):689-701. doi: 10.1080/14787210.2017.1333422. Epub 2017 May 29. Expert Rev Anti Infect Ther. 2017. PMID: 28524748 Review.
Cited by
-
Mass chemoprophylaxis for control of outbreaks of meningococcal disease.Lancet Infect Dis. 2018 Sep;18(9):e272-e281. doi: 10.1016/S1473-3099(18)30124-5. Epub 2018 May 29. Lancet Infect Dis. 2018. PMID: 29858150 Free PMC article. Review.
-
Safety and immunological outcomes following human inoculation with nontypeable Haemophilus influenzae.J Infect Dis. 2013 Sep 1;208(5):728-38. doi: 10.1093/infdis/jit238. Epub 2013 May 28. J Infect Dis. 2013. PMID: 23715660 Free PMC article.
-
Secondary prevention of meningococcal disease.BMJ. 1996 Mar 9;312(7031):591-2. doi: 10.1136/bmj.312.7031.591. BMJ. 1996. PMID: 8595321 Free PMC article. No abstract available.
-
Update on meningococcal disease with emphasis on pathogenesis and clinical management.Clin Microbiol Rev. 2000 Jan;13(1):144-66, table of contents. doi: 10.1128/CMR.13.1.144. Clin Microbiol Rev. 2000. PMID: 10627495 Free PMC article. Review.
-
Emergence of a new virulent clone within the electrophoretic type 5 complex of serogroup B meningococci in Norway.Clin Diagn Lab Immunol. 1995 May;2(3):314-21. doi: 10.1128/cdli.2.3.314-321.1995. Clin Diagn Lab Immunol. 1995. PMID: 7664178 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical